This story was originally published in XXIV magazine 2018
Sitting in Popinjay’s, the rooftop restaurant at The Murray Hong Kong in Central, Gene Shigekawa, managing partner of biotech company Maz World, is in deep thought.
“I just calculated I took a hundred flights in the last year,” he says. That means he’s on a flight every three days. “Well, that number includes transit flights, too,” he chuckles.
The managing partner of Japanese biotech company Maz World is constantly on the move, focusing on commercialising antibodies derived from ostrich eggs for treatment of people with diabetes.
Sitting in Popinjay’s, the rooftop restaurant at The Murray Hong Kong in Central, Gene Shigekawa, managing partner of biotech company Maz World, is in deep thought.
“I just calculated I took a hundred flights in the last year,” he says. That means he’s on a flight every three days. “Well, that number includes transit flights, too,” he chuckles.
The managing partner of Japanese biotech company Maz World is constantly on the move, focusing on commercialising antibodies derived from ostrich eggs for treatment of people with diabetes.
Category
✨
People